Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program
Stock Information for Larimar Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.